Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages

Ocular Therapeutix, Inc. (NASDAQ:OCUL) has received a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $22.3333.

OCUL has been the topic of a number of recent research reports. Scotiabank cut their price objective on shares of Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating on the stock in a report on Wednesday, August 6th. JMP Securities raised their price target on Ocular Therapeutix from $20.00 to $29.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 1st. Chardan Capital reaffirmed a “buy” rating and issued a $21.00 target price on shares of Ocular Therapeutix in a report on Wednesday, November 5th. Cowen reissued a “buy” rating on shares of Ocular Therapeutix in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Monday.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock traded up $0.01 on Thursday, reaching $12.14. The stock had a trading volume of 2,367,175 shares, compared to its average volume of 2,096,539. The business’s 50 day moving average is $11.69 and its two-hundred day moving average is $10.87. The company has a market cap of $2.59 billion, a P/E ratio of -9.48 and a beta of 1.53. The company has a current ratio of 10.10, a quick ratio of 10.02 and a debt-to-equity ratio of 0.23. Ocular Therapeutix has a 1 year low of $5.78 and a 1 year high of $13.85.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. The firm had revenue of $14.54 million during the quarter, compared to analysts’ expectations of $14.57 million. Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%. As a group, research analysts anticipate that Ocular Therapeutix will post -0.98 EPS for the current year.

Insider Transactions at Ocular Therapeutix

In other news, insider Todd Anderman sold 11,132 shares of the firm’s stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $12.34, for a total transaction of $137,368.88. Following the transaction, the insider directly owned 87,568 shares of the company’s stock, valued at approximately $1,080,589.12. This trade represents a 11.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Peter Kaiser sold 9,653 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $11.03, for a total transaction of $106,472.59. Following the completion of the sale, the insider directly owned 194,440 shares of the company’s stock, valued at $2,144,673.20. The trade was a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 32,353 shares of company stock worth $373,034. 2.30% of the stock is currently owned by insiders.

Institutional Trading of Ocular Therapeutix

Several large investors have recently made changes to their positions in OCUL. Nisa Investment Advisors LLC grew its stake in shares of Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,392 shares during the period. Brooklyn Investment Group raised its stake in shares of Ocular Therapeutix by 151.5% during the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 3,155 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 893 shares during the period. Trust Co. of Vermont boosted its position in Ocular Therapeutix by 16.1% during the second quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Quarry LP acquired a new position in shares of Ocular Therapeutix in the third quarter worth $80,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.